Microcap Ledger Boundless Bio, Inc. $BOLD
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- La Jolla, CA
- Fiscal year end
- December 31
- Shares outstanding
- 22,747,985 [10-Q 2026-08-07]
What the company doesAI summary of filing
Boundless Bio is a clinical-stage oncology company developing small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to treat cancers with oncogene amplifications driven by extrachromosomal DNA (ecDNA). The company uses its proprietary Spyglass platform to identify targets essential for ecDNA function, then designs drugs to inhibit those targets. Its lead program, BBI-940, a kinesin degrader, entered a Phase 1 trial in February 2026 in patients with ER+/HER2- breast cancer and triple-negative breast cancer; the company expects initial clinical data within its existing cash runway. The company is pre-revenue and has not yet generated product sales. [10-K 2026-03-09]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$37.25M | −$35.95M | $20.21M | [S-4 2026-10-08] |
| FY ended Dec 2025 | — | −$58.20M | −$46.66M | $17.87M | [S-4 2026-10-08] |
| FY ended Dec 2024 | — | −$65.36M | −$60.84M | $26.59M | [S-4 2026-10-08] |
- Quarterly cash burn
- −$17.97M
- Cash runway Estimate
- ~3.4 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-06 | 22,300,043 | [10-Q 2024-11-07] |
| 2025-03-21 | 22,300,043 | [10-K 2025-03-27] |
| 2025-05-06 | 22,385,611 | [10-Q 2025-05-09] |
| 2025-07-31 | 22,385,611 | [10-Q 2025-08-05] |
| 2025-10-31 | 22,385,611 | [10-Q 2025-11-05] |
| 2026-03-02 | 22,407,251 | [10-K 2026-03-09] |
| 2026-05-05 | 22,464,111 | [10-Q 2026-05-08] |
| 2026-08-05 | 22,747,985 | [10-Q 2026-08-07] |
- Shelf registration
- S-3 filed 2025-04-01; declared effective 2025-04-10 [S-3 2025-04-01]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-26 | Tang Kevin | sell | 18,300 | $2.97 | [4 2026-08-28] |
| 2026-07-21 | Tang Kevin | buy | 2,975 | $2.44 | [4 2026-07-21] |
| 2026-07-20 | Tang Kevin | buy | 1,623 | $2.44 | [4 2026-07-21] |
| 2026-07-17 | Tang Kevin | buy | 265 | $2.44 | [4 2026-07-21] |
| 2026-07-16 | Tang Kevin | buy | 18,491 | $2.44 | [4 2026-07-16] |
| 2026-07-15 | Tang Kevin | buy | 1,600 | $2.44 | [4 2026-07-16] |
| 2026-07-14 | Tang Kevin | buy | 43,878 | $2.43 | [4 2026-07-16] |
| 2026-07-13 | Tang Kevin | buy | 48,211 | $2.42 | [4 2026-07-13] |
| 2026-07-10 | Tang Kevin | buy | 43,367 | $2.43 | [4 2026-07-13] |
| 2026-07-09 | Tang Kevin | buy | 7 | $2.48 | [4 2026-07-13] |
| 2026-07-08 | Tang Kevin | buy | 14,338 | $2.46 | [4 2026-07-08] |
| 2026-07-07 | Tang Kevin | buy | 15,810 | $2.48 | [4 2026-07-08] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-28 | 8-K | Material agreement entered |
| 2026-08-27 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-07 | 10-Q | Quarterly report |
| 2026-06-29 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-06-23 | 8-K | Material agreement entered; Exit or disposal costs; Unregistered sale of equity |
| 2026-06-17 | 8-K | Shareholder vote results |
| 2026-05-08 | 10-Q | Quarterly report |
| 2026-05-08 | 8-K | Results of operations |
| 2026-04-28 | DEF 14A | Proxy statement |
| 2026-04-13 | 8-K | Material agreement terminated; New financial obligation |
Alerts for $BOLD
Email me when Boundless Bio, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.